Company Filing History:
Years Active: 2020-2022
Title: Wouter Beumer: Innovator in Oligonucleotide Therapy
Introduction
Wouter Beumer is a notable inventor based in Voorburg, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of therapies for genetic disorders. With a total of 2 patents, Beumer is recognized for his innovative approaches to medical treatments.
Latest Patents
Beumer's latest patents focus on oligonucleotides that match COL7A1 exon 73 for the therapy of epidermolysis bullosa. These antisense oligonucleotides are designed to prevent or reduce the inclusion of exon 73 into the human COL7A mRNA. They are characterized by several features: the oligonucleotide's sequence includes at most two CpG sequences, the length does not exceed 24 nucleotides, and they are capable of annealing to the (SRp40/SC35 binding/ESE) element in exon 73. Additionally, these oligonucleotides can be oligoribonucleotides with modified internucleosidic linkages, such as phosphorothioate linkages.
Career Highlights
Wouter Beumer is currently associated with Wings Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in addressing the challenges posed by genetic disorders, particularly those affecting skin integrity.
Collaborations
Beumer collaborates with esteemed colleagues, including Elisabeth Marlene Haisma and Marko Potman. Their combined expertise enhances the innovative potential of their projects and contributes to the advancement of therapeutic solutions.
Conclusion
Wouter Beumer's contributions to the field of biotechnology, particularly through his patents on oligonucleotide therapies, highlight his role as a key innovator. His work not only showcases his inventive spirit but also holds promise for improving the lives of individuals affected by genetic disorders.